We have collected information about Cellular Delivery In Vivo Of Sirna-Based Therapeutics for you. Follow the links to find out details on Cellular Delivery In Vivo Of Sirna-Based Therapeutics.
https://www.ncbi.nlm.nih.gov/pubmed/19075737
RNAi is mediated by small interfering RNAs (siRNA), and thus siRNA delivery in vivo is of critical importance for its implementation.Author: A. Aigner
https://www.ingentaconnect.com/contentone/ben/cpd/2008/00000014/00000034/art00002
RNAi is mediated by small interfering RNAs (siRNA), and thus siRNA delivery in vivo is of critical importance for its implementation.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2977003/
Jun 11, 2010 · Under in vivo conditions, intratumoral injection of F105-P–siRNA showed selective cellular delivery to the HIV envelope-expressing B16 melanoma cells without delivery to the adjacent normal tissue or the envelope-negative B16 cells. Similarly, intratumoral and systemic injection of F105-P–siRNA targeting c-myc, MDM2, and VEGF inhibited the ...Author: Jie Wang, Ze Lu, M. Guillaume Wientjes, Jessie L.-S. Au
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4504743/
Jun 29, 2015 · 3. Clinical experience with siRNA-based therapeutics. After validation in in vivo models, siRNA-based therapies were introduced into clinical trials. Since the discovery of RNAi, there have been more than 50 clinical trials involving 26 different siRNAs (Table 1). Initial studies were conducted in diseases requiring localized delivery.Author: Gulnihal Ozcan, Bulent Ozpolat, Robert L. Coleman, Anil K. Sood, Gabriel Lopez-Berestein
https://www.sciencedirect.com/science/article/pii/S0169409X19300547
This was an important milestone for the field of siRNA delivery that opens the door for additional siRNA drugs. Currently, >20 small interfering RNA (siRNA)-based therapies are in clinical trials for a wide variety of diseases including cancers, genetic disorders, and viral infections.Author: Yizhou Dong, Daniel J. Siegwart, Daniel G. Anderson
https://www.nature.com/articles/s41573-019-0017-4
Mar 07, 2019 · The recent approval of the first RNA interference (RNAi)-based therapy has generated considerable excitement in the field. Here, Rossi and colleagues discuss key advances in the design and ...Author: Ryan L. Setten, Ryan L. Setten, John J. Rossi, John J. Rossi, Si-ping Han, Si-ping Han
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3375670/
Jun 25, 2012 · Off-target silencing is undesirable as it can lead to dangerous mutation of gene expression and unexpected cell transformation. Recent studies have demonstrated that most off-target silencing is a result of homology with six to seven nucleotides in the “seed region” of the siRNA sequence [ 37, 38 ].Author: Gavrilov K, Saltzman Wm
Searching for Cellular Delivery In Vivo Of Sirna-Based Therapeutics?
You can just click the links above. The data is collected for you.
